US 12,240,904 B2
Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumors
Lianshan Zhang, Jiangsu (CN); Qing Yang, Jiangsu (CN); Quanren Wang, Jiangsu (CN); Xiaoxing Huang, Jiangsu (CN); Cheng Liao, Jiangsu (CN); Changyong Yang, Jiangsu (CN); Dingwei Ye, Jiangsu (CN); and Xiaohua Wu, Jiangsu (CN)
Assigned to Jiangsu Hengrui Medicine Co., Ltd., Jiangsu (CN); and Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu (CN)
Appl. No. 17/288,894
Filed by Jiangsu Hengrui Medicine Co., Ltd., Jiangsu (CN); and Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu (CN)
PCT Filed Nov. 5, 2019, PCT No. PCT/CN2019/115608
§ 371(c)(1), (2) Date Apr. 26, 2021,
PCT Pub. No. WO2020/093993, PCT Pub. Date May 14, 2020.
Claims priority of application No. 201811313004.X (CN), filed on Nov. 6, 2018.
Prior Publication US 2022/0251203 A1, Aug. 11, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 31/437 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2818 (2013.01) [A61K 31/437 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01)] 16 Claims
 
1. A method of treating tumors in a patient in need thereof, the method comprising administering to the patient an anti-PD-1 antibody or antigen-binding fragment thereof and famitinib or a pharmaceutically acceptable salt thereof, wherein the light chain variable region of the PD-1 antibody comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6 respectively, and the heavy chain variable region of the PD-1 antibody comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 respectively.